We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Turtle Beach, BioLife Solutions, IntriCon and Medifast
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Turtle Beach Corp. (HEAR - Free Report) , BioLife Solutions, Inc. (BLFS - Free Report) , IntriCon Corporation and Medifast, Inc. (MED - Free Report) .
Trump’s Approval Rating Buoy Wall Street: 4 Top Gainers
Per the latest survey by The Wall Street Journal and NBC News on Aug 26, President Donald Trump’s approval rating remained unaffected by the recent controversies the he found himself embroiled in. This comes as no surprise, given the fact that Trump has delivered on a lot of his promises dating back to his campaign trail.
Moreover, this bodes well for the economy and in turn the stock market because major indices have breached numerous records post Trump’s ascension to America’s presidency. Further, the U.S. GDP in the second quarter, expanded at its fastest pace in the last four years. Given such factors, investing in stocks of companies headquartered within the United States seems prudent.
Trump’s Job Approval Rating Remains Strong
A recent survey on Donald Trump’s performance as the President revealed that about 44% of Americans had favorable views. Notably, the survey was taken after Paul Manafort, Trump’s former campaign chairman, pleaded guilty to fraud charges and Michael Cohen, Trump’s former lawyer, was convicted on tax and campaign finance fraud.
Further, earlier last week, just before the legal proceedings, the NBC conducted job approval rating survey on Trump stood at 46%. Despite a 2% decline, the change is well within the survey’s margin of error. It therefore does not change the fact that almost half of the Americans favor Donald Trump.
Trump’s pro-growth policies have proven a catalyst to economic growth. The landmark tax reform bill has provided the much-required impetus to stocks trading on American bourses. Notably, the Dow Jones, S&P 500 and the Nasdaq have gained 4.7%, 7.6% and 15.4%, respectively in the year-to-date time frame.
U.S. GDP Growth Fastest Since 2014
According to the Department of Commerce’s second estimate, U.S. GDP increased at a 4.2% pace in the second quarter, reflecting an upward revision from 4.1% initially thought of. This is the sharpest pace of growth experienced since the 4.9% pace registered in the third quarter of 2014. Such developments also indicate that the economy is on track to achieve annual growth of 3%, as targeted by Trump. Additionally, for the first half of 2018, the U.S. economy expanded at 3.2%.
Strength in software investment and a reduction in import bill propelled economic growth in the second quarter. This offset a minor downward revision to consumer spending.
4 Hot Choices
Trump’s pro-growth agenda has worked wonders for the economy as a whole. The U.S. GDP in the second quarter notched up its highest pace of growth in the last four years. This indicates that the economy is on track to achieve Trump’s targeted 3% annual rate of growth. Finally, major market indices have all gained significantly since Trump’s ascension to presidency.
In this context, we have selected four stocks that are expected to gain from these factors. These stocks carry a Zacks Rank #1 (Strong Buy) and have year-to-date (YTD) returns of more than 100%. You can seethe complete list of today’s Zacks #1 Rank stocks here.
Turtle Beach Corp. is a provider of gaming headset solutions for various platforms such as video game and entertainment consoles, handheld consoles as well as personal computers.
The company is based out of San Diego, CA. The expected earnings growth rate for the current year is more than 100%. The Zacks Consensus Estimate for the current year has also improved more than 100% over the past 60 days.
BioLife Solutions, Inc. is a developer and manufacturer of patented tissue hypothermic storage and cryopreservation freeze products for cells, tissues, and organs.
The company is based out of Bothell, WA. The expected earnings growth rate for the current year is more than 100%. The Zacks Consensus Estimate for the current year has also improved more than 100% over the past 60 days.
IntriCon Corporation is a manufacturer and developer of body-worn devices in the United States as well as across the globe.
The company is based out of Arden Hills, MN. The expected earnings growth rate for the current year is more than 100%. The Zacks Consensus Estimate for the current year has improved 52.1% over the past 60 days.
Medifast, Inc. is a manufacturer and distributor of weight loss, weight management, healthy living products as well as other consumable health and nutritional products.
The company is based out of Baltimore, MD. The expected earnings growth rate for the current year is 96.51%. The Zacks Consensus Estimate for the current year has improved 23.3% over the past 60 days.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Turtle Beach, BioLife Solutions, IntriCon and Medifast
For Immediate Release
Chicago, IL – September 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Turtle Beach Corp. (HEAR - Free Report) , BioLife Solutions, Inc. (BLFS - Free Report) , IntriCon Corporation and Medifast, Inc. (MED - Free Report) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Friday’s Analyst Blog:
Trump’s Approval Rating Buoy Wall Street: 4 Top Gainers
Per the latest survey by The Wall Street Journal and NBC News on Aug 26, President Donald Trump’s approval rating remained unaffected by the recent controversies the he found himself embroiled in. This comes as no surprise, given the fact that Trump has delivered on a lot of his promises dating back to his campaign trail.
Moreover, this bodes well for the economy and in turn the stock market because major indices have breached numerous records post Trump’s ascension to America’s presidency. Further, the U.S. GDP in the second quarter, expanded at its fastest pace in the last four years. Given such factors, investing in stocks of companies headquartered within the United States seems prudent.
Trump’s Job Approval Rating Remains Strong
A recent survey on Donald Trump’s performance as the President revealed that about 44% of Americans had favorable views. Notably, the survey was taken after Paul Manafort, Trump’s former campaign chairman, pleaded guilty to fraud charges and Michael Cohen, Trump’s former lawyer, was convicted on tax and campaign finance fraud.
Further, earlier last week, just before the legal proceedings, the NBC conducted job approval rating survey on Trump stood at 46%. Despite a 2% decline, the change is well within the survey’s margin of error. It therefore does not change the fact that almost half of the Americans favor Donald Trump.
Trump’s pro-growth policies have proven a catalyst to economic growth. The landmark tax reform bill has provided the much-required impetus to stocks trading on American bourses. Notably, the Dow Jones, S&P 500 and the Nasdaq have gained 4.7%, 7.6% and 15.4%, respectively in the year-to-date time frame.
U.S. GDP Growth Fastest Since 2014
According to the Department of Commerce’s second estimate, U.S. GDP increased at a 4.2% pace in the second quarter, reflecting an upward revision from 4.1% initially thought of. This is the sharpest pace of growth experienced since the 4.9% pace registered in the third quarter of 2014. Such developments also indicate that the economy is on track to achieve annual growth of 3%, as targeted by Trump. Additionally, for the first half of 2018, the U.S. economy expanded at 3.2%.
Strength in software investment and a reduction in import bill propelled economic growth in the second quarter. This offset a minor downward revision to consumer spending.
4 Hot Choices
Trump’s pro-growth agenda has worked wonders for the economy as a whole. The U.S. GDP in the second quarter notched up its highest pace of growth in the last four years. This indicates that the economy is on track to achieve Trump’s targeted 3% annual rate of growth. Finally, major market indices have all gained significantly since Trump’s ascension to presidency.
In this context, we have selected four stocks that are expected to gain from these factors. These stocks carry a Zacks Rank #1 (Strong Buy) and have year-to-date (YTD) returns of more than 100%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Turtle Beach Corp. is a provider of gaming headset solutions for various platforms such as video game and entertainment consoles, handheld consoles as well as personal computers.
The company is based out of San Diego, CA. The expected earnings growth rate for the current year is more than 100%. The Zacks Consensus Estimate for the current year has also improved more than 100% over the past 60 days.
BioLife Solutions, Inc. is a developer and manufacturer of patented tissue hypothermic storage and cryopreservation freeze products for cells, tissues, and organs.
The company is based out of Bothell, WA. The expected earnings growth rate for the current year is more than 100%. The Zacks Consensus Estimate for the current year has also improved more than 100% over the past 60 days.
IntriCon Corporation is a manufacturer and developer of body-worn devices in the United States as well as across the globe.
The company is based out of Arden Hills, MN. The expected earnings growth rate for the current year is more than 100%. The Zacks Consensus Estimate for the current year has improved 52.1% over the past 60 days.
Medifast, Inc. is a manufacturer and distributor of weight loss, weight management, healthy living products as well as other consumable health and nutritional products.
The company is based out of Baltimore, MD. The expected earnings growth rate for the current year is 96.51%. The Zacks Consensus Estimate for the current year has improved 23.3% over the past 60 days.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.